Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,064 Hematology
clinical trials

Hematology, Oncology Clinical Trial
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
West Virginia University Hospitals Inc.
970
mi
from
Morgantown, WV
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
Status: Enrolling, Phase III
Updated: 12/31/1969
Louisiana State University Health Sciences Center-Shreveport
429
mi
from
Shreveport, LA
Click here to add this to my saved trials
Recurrent Plasma Cell Myeloma Clinical Trial
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Status: Enrolling, Phase I
Updated: 2/3/2016
Aspirus UW Cancer Center
618
mi
from
Wisconsin Rapids, WI
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Site US10005
894
mi
from
Cleveland, OH
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Status: Enrolling, Phase II
Updated: 12/31/1969
San Juan Oncology Associates
575
mi
from
Farmington, NM
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Status: Enrolling, Phase II
Updated: 12/31/1969
Compassionate Care Research Group, Inc.
1160
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling, Phase
Updated: 12/31/1969
Henry Ford Hospital SC
841
mi
from
Detroit, MI
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling, Phase
Updated: 12/31/1969
Penn State University / Milton S. Hershey Medical Center Penn State Cancer Institute
1145
mi
from
Hershey, PA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling, Phase
Updated: 12/31/1969
Oncology Consultants Oncology Consultants, P.A.
569
mi
from
Houston, TX
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling, Phase
Updated: 12/31/1969
Oschner Clinic Foundation
694
mi
from
New Orleans, LA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling, Phase
Updated: 12/31/1969
Nebraska Cancer Specialist/Missouri Valley Cancer Consortium
259
mi
from
Omaha, NE
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Status: Enrolling, Phase
Updated: 12/31/1969
Mayo Clinic
840
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
572
mi
from
Houston, TX
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Cancer Indications
Status: Enrolling, Phase I, II
Updated: 12/31/1969
John Theurer Cancer Center At Hackensack UMC
1284
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Acquired Hemophilia A Clinical Trial
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Status: Enrolling, Phase
Updated: 3/22/2018
University of Utah Health Sciences Center
777
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Myeloid and Monocytic Leukemia Clinical Trial
CAMELLIA: Anti-CD47 Antibody Therapy in Relapsed/Refractory Acute Myeloid Leukaemia
Status: Enrolling, Phase I
Updated: 2/4/2016
Stanford Cancer Institute
1329
mi
from
Stanford, CA
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Status: Enrolling, Phase I
Updated: 7/24/2017
Texas Children's Hospital
572
mi
from
Houston, TX
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Status: Enrolling, Phase I
Updated: 7/24/2017
Seattle Children'S Research Institute
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling, Phase III
Updated: 12/31/1969
Site US10021
1443
mi
from
Boston, MA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling, Phase III
Updated: 12/31/1969
Site US10013
609
mi
from
Chicago, IL
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling, Phase III
Updated: 12/31/1969
Site US10003
1112
mi
from
Fairfax, VA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling, Phase III
Updated: 12/31/1969
Site US10046
1193
mi
from
Syracuse, NY
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Status: Enrolling, Phase III
Updated: 12/31/1969
Site US10029
974
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling, Phase III
Updated: 12/31/1969
Duke University
1052
mi
from
Durham, NC
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling, Phase III
Updated: 12/31/1969
Johns Hopkins Hospital
1149
mi
from
Baltimore, MD
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling, Phase III
Updated: 12/31/1969
Cedars Sinai Heart Institute
1175
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling, Phase III
Updated: 12/31/1969
UAB Hospital
676
mi
from
Birmingham, AL
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling, Phase III
Updated: 12/31/1969
Boston Med Ctr
1443
mi
from
Boston, MA
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling, Phase III
Updated: 12/31/1969
Boston University Medical Center
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling, Phase III
Updated: 12/31/1969
Northwestern Medical Group
611
mi
from
Chicago, IL
Click here to add this to my saved trials
Transthyretin (TTR) Amyloid Cardiomyopathy Clinical Trial
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
Status: Enrolling, Phase III
Updated: 12/31/1969
Penn Presbyterian Medical Center
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML
Status: Enrolling, Phase III
Updated: 12/31/1969
Baylor Charles A Sammons Cancer Center
348
mi
from
Dallas, TX
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML
Status: Enrolling, Phase III
Updated: 12/31/1969
Yale Cancer Center
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML
Status: Enrolling, Phase III
Updated: 12/31/1969
Stony Brook University
1358
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Status: Enrolling, Phase I
Updated: 12/31/1969
Northwestern Memorial
611
mi
from
Chicago, IL
Click here to add this to my saved trials
Hemophilia A Clinical Trial
BAX 855 Previously Untreated Patient (PUP)
Status: Enrolling, Phase III
Updated: 4/19/2018
Primary Children's Medical Center
777
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Hemophilia A Clinical Trial
BAX 855 Previously Untreated Patient (PUP)
Status: Enrolling, Phase III
Updated: 4/19/2018
Phoenix Children's Hospital
849
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
The Oronasal Microbiota in Pediatric Oncology Patients
Status: Enrolling, Phase
Updated: 12/31/1969
St. Jude Children's Research Hospital
468
mi
from
Memphis, TN
Click here to add this to my saved trials
Chronic Graft Versus Host Disease Clinical Trial
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD
Status: Enrolling, Phase III
Updated: 12/31/1969
Barbara Ann Karmanos Cancer Institute
841
mi
from
Detroit, MI
Click here to add this to my saved trials
Chronic Graft Versus Host Disease Clinical Trial
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD
Status: Enrolling, Phase III
Updated: 12/31/1969
Loyola University Chicago
612
mi
from
Chicago, IL
Click here to add this to my saved trials
Chronic Graft Versus Host Disease Clinical Trial
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Louisville
656
mi
from
Louisville, KY
Click here to add this to my saved trials
Chronic Graft Versus Host Disease Clinical Trial
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD
Status: Enrolling, Phase III
Updated: 12/31/1969
The Mayo Clinic
515
mi
from
Rochester, MN
Click here to add this to my saved trials
Hematology, Neurology Clinical Trial
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Status: Enrolling, Phase
Updated: 12/31/1969
Vanderbilt University Medical Center
618
mi
from
Nashville, TN
Click here to add this to my saved trials
Hematology, Neurology Clinical Trial
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Status: Enrolling, Phase
Updated: 12/31/1969
University of Kansas Medical Center
190
mi
from
Kansas City, KS
Click here to add this to my saved trials
Hematology, Neurology Clinical Trial
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Status: Enrolling, Phase
Updated: 12/31/1969
Stanford University
1329
mi
from
Stanford, CA
Click here to add this to my saved trials
Graft vs Host Disease Clinical Trial
Study of PRO 140 for Prophylaxis of Acute GVHD in Patients Undergoing RIC Allogenic Stem-Cell Transplantaton
Status: Enrolling, Phase II
Updated: 12/31/1969
Wake Forest Baptist Health
976
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Hematology, Neurology Clinical Trial
Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)
Status: Enrolling
Updated: 12/31/1969
University of Michigan
808
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Hematology Clinical Trial
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Status: Enrolling, Phase II
Updated: 12/31/1969
Grady Memorial Hospital
801
mi
from
Atlanta, GA
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
University of Maryland School of Med
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Cleveland Clinic Foundation
898
mi
from
Cleveland, OH
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Hackensack University Medical Center
1285
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology Clinical Trial
A Randomized Multicenter Study for Isolated Skin Vasculitis
Status: Enrolling, Phase II
Updated: 12/31/1969
Penn State Hershey Medical Center
1147
mi
from
Hershey, PA
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Status: Enrolling, Phase II
Updated: 12/31/1969
Winship Cancer Institute at Emory University
803
mi
from
Atlanta, GA
Click here to add this to my saved trials
Plasma Cell Myeloma Clinical Trial
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
Status: Enrolling, Phase II
Updated: 12/31/1969
The Mayo Clinic
515
mi
from
Rochester, MN
Click here to add this to my saved trials
Smoldering Multiple Myeloma Clinical Trial
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Status: Enrolling, Phase I
Updated: 12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status: Enrolling, Phase I
Updated: 12/31/1969
University of California-Davis Comprehensive Cancer Ctr
1281
mi
from
Sacramento, CA
Click here to add this to my saved trials
Homocystinuria Due to CBS Deficiency Clinical Trial
Natural History Study of Cystathionine Beta-synthase Deficiency Homocystinuria (CBSDH)
Status: Enrolling, Phase
Updated: 12/31/1969
Children's Hospital of Philadelphia
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Homocystinuria Due to CBS Deficiency Clinical Trial
Natural History Study of Cystathionine Beta-synthase Deficiency Homocystinuria (CBSDH)
Status: Enrolling, Phase
Updated: 12/31/1969
Children's Hospital Colorado
400
mi
from
Aurora, CO
Click here to add this to my saved trials
Homocystinuria Due to CBS Deficiency Clinical Trial
Natural History Study of Cystathionine Beta-synthase Deficiency Homocystinuria (CBSDH)
Status: Enrolling, Phase
Updated: 12/31/1969
Indiana University School of Medicine
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Mount Sinai Hospital
1289
mi
from
New York, NY
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Hematology, Reproductive Clinical Trial
Molecular Determinants of Coronaruy Artery Disease
Status: Enrolling, Phase
Updated: 12/31/1969
Cleveland Clinic
898
mi
from
Cleveland, OH
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia
Status: Enrolling, Phase I
Updated: 12/31/1969
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia
Status: Enrolling, Phase I
Updated: 12/31/1969
Los Angeles County-USC Medical Center
1166
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Status: Enrolling, Phase
Updated: 12/31/1969
University Medical Center of Southern Nevada
962
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Status: Enrolling, Phase
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
1113
mi
from
Richmond, VA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Status: Enrolling, Phase
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
571
mi
from
San Antonio, TX
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Status: Enrolling, Phase
Updated: 12/31/1969
Summerlin Hospital Medical Center
960
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Florida
1049
mi
from
Gainesville, FL
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling, Phase
Updated: 12/31/1969
Northside Hospital
798
mi
from
Atlanta, GA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling, Phase
Updated: 12/31/1969
Penn State Hershey Medical Center
1147
mi
from
Hershey, PA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling, Phase
Updated: 12/31/1969
UCLA
1177
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling, Phase
Updated: 12/31/1969
Vanderbilt University
618
mi
from
Nashville, TN
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling, Phase
Updated: 12/31/1969
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status: Enrolling, Phase
Updated: 12/31/1969
Wake Forest Baptist Hospital
974
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
AML Clinical Trial
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
SEL24/MEN1703 in Patients With Acute Myeloid Leukemia
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Northside Hospital
798
mi
from
Atlanta, GA
Click here to add this to my saved trials
Previously Untreated Acute Myeloid Leukemia Clinical Trial
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Emory University
801
mi
from
Atlanta, GA
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients
Status: Enrolling, Phase II
Updated: 12/31/1969
Tennessee Oncology, PLLC
558
mi
from
Nashville, TN
Click here to add this to my saved trials
Hemophilia A, Congenital Clinical Trial
Alphanate in Immune Tolerance Induction Therapy
Status: Enrolling, Phase II
Updated: 12/31/1969
Emory University
801
mi
from
Atlanta, GA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
Status: Enrolling, Phase
Updated: 12/31/1969
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
MMRF Molecular Profiling Protocol
Status: Enrolling, Phase
Updated: 12/31/1969
University of Chicago
609
mi
from
Chicago, IL
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
MMRF Molecular Profiling Protocol
Status: Enrolling, Phase
Updated: 12/31/1969
Hackensack University Medical Center
1285
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
MMRF Molecular Profiling Protocol
Status: Enrolling, Phase
Updated: 12/31/1969
Mayo Clinic Rochester
515
mi
from
Rochester, MN
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
MMRF Molecular Profiling Protocol
Status: Enrolling, Phase
Updated: 12/31/1969
UCSF Medical Center
1340
mi
from
San Francisco, CA
Click here to add this to my saved trials
Hematology Clinical Trial
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
974
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hematology Clinical Trial
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Rochester
1121
mi
from
Rochester, NY
Click here to add this to my saved trials
Hematology Clinical Trial
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Healthcare of Atlanta - Egleston
803
mi
from
Atlanta, GA
Click here to add this to my saved trials
Hematology Clinical Trial
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling, Phase II
Updated: 12/31/1969
Riley Hospital for Children
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Hematology Clinical Trial
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of Wisconsin
630
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Hematology Clinical Trial
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling, Phase II
Updated: 12/31/1969
Columbia University Herbert Irving Cancer Center
1290
mi
from
New York, NY
Click here to add this to my saved trials
Hematology Clinical Trial
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
153
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Hematology Clinical Trial
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling, Phase I, II
Updated: 12/31/1969
National Institutes of Health Clinical Center
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling, Phase II
Updated: 12/31/1969
Cleveland Clinic
898
mi
from
Cleveland, OH
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Alphonsus Regional Medical Center
1041
mi
from
Boise, ID
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling, Phase II
Updated: 12/31/1969
Integris Southwest Medical Center
153
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling, Phase II
Updated: 12/31/1969
Redlands Community Hospital
1110
mi
from
Redlands, CA
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling, Phase II
Updated: 12/31/1969
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Click here to add this to my saved trials
MPN (Myeloproliferative Neoplasms) Clinical Trial
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Status: Enrolling, Phase II
Updated: 12/31/1969
Prairie Lakes Health Care System
495
mi
from
Watertown, SD
Click here to add this to my saved trials
Hemophilia A Clinical Trial
An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
Status: Enrolling, Phase
Updated: 3/26/2018
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Click here to add this to my saved trials
Hemophilia A Clinical Trial
An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
Status: Enrolling, Phase
Updated: 3/26/2018
University of Utah
777
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
1 … 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 … 121